Oxford Nanopore Technologies, Inc.

Oxford Nanopore Technologies, Inc., a foreign-owned biotechnology company based in New York, supplies next-generation genomic sequencing instruments, consumables, reagents, and support services to federal research agencies as a prime contractor on full-and-open purchase orders and indefinite delivery vehicles (100% of recent awards are prime). The company holds no socioeconomic certifications and competes across civilian health, research, and agricultural agencies without set-aside restrictions.

Oxford Nanopore's federal capability portfolio centers on nanopore-based long-read DNA and RNA sequencing platforms and associated consumables. The company delivers two primary product categories: sequencing instruments (GridION MK1, PromethION series including PromethION 2 Solo and PromethION 24/48 variants, and portable MinION systems) priced from $10,000 to $262,000 per unit, and consumables (flow cell packs, sequencing kits, ligation and rapid barcoding kits, library preparation reagents) typically valued at $12,000 to $90,000 per order. Representative recent awards include a $295,137 firm-fixed-price purchase order from the FDA for a PromethION 2 Solo lease and consumables through November 2028; a $599,755 purchase order from the National Institute on Aging for long-read RNA sequencing kits supporting the Center for Alzheimer's Disease and Related Dementias' Induced Pluripotent Stem Cell Neurodegenerative Disease Initiative; a $232,150 purchase order from the National Institute on Drug Abuse for PromethION flow cell packs; and a $125,000 purchase order from USDA Agricultural Research Service for annual software licenses and device warranties on GridION sequencers in Stoneville, Mississippi.

Customer concentration is substantial and dispersed across NIH institutes. The National Institute on Drug Abuse anchors the dollar ranking with 7 awards worth $4.3 million combined potential value, followed by the National Institute on Aging (27 awards, $2.8 million), CDC Pittsburgh (62 awards, $2 million), and the National Human Genome Research Institute (38 awards, $1.6 million). These top five agencies account for 52% of combined potential value across Oxford Nanopore's recent federal footprint. By volume, CDC Pittsburgh leads with 62 awards (15% of the total), though that volume translates to a lower per-order dollar magnitude relative to the NIH institute concentration by value. FDA, USDA Agricultural Research Service, and the Veterans Administration represent secondary customer clusters.

Oxford Nanopore holds two active parent vehicles. A $325,000 Blanket Purchase Agreement with the Defense Health Agency (awarded March 1, 2024, expiring February 28, 2029) covers reagents, equipment, warranty, and license services. A $740,000 Indefinite Delivery Contract with USDA Animal and Plant Health Inspection Service (awarded September 1, 2024, expiring August 31, 2029) supplies Oxford Nanopore consumables including reagents, flow cells, and sequencing accessories. A third BPA with HHS Office of Acquisitions and Grants (awarded September 19, 2024, ceiling $66,990, expiring September 19, 2028) procures MinION portable sequencer reagents and supplies. Task-order utilization on these vehicles is modest relative to ceiling valuations; the Defense Health Agency BPA and USDA IDC have drawn six and zero task orders respectively in recent activity, indicating these are convenience vehicles for streamlined procurement rather than high-velocity ordering mechanisms.

Activity has declined year over year across the portfolio. Oxford Nanopore received 54 awards in 2022, 59 in 2023, 38 in 2024, 28 in 2025, and 17 through September 2026 — a trend consistent with maturing procurement patterns and reduced COVID-related sequencing demand. Within the next twenty-four months, 17 awards carrying $2.9 million in combined potential value reach ultimate completion, representing moderate recompete exposure.

The vendor portfolio is heavily concentrated in consumables and laboratory supplies. NAICS 325413 (Analytical Laboratory Instrument Manufacturing) represents 235 of 400 awards (59%), and PSC 6550 (Laboratory Equipment and Supplies) accounts for 244 awards (61%). Secondary concentrations in maintenance and repair services (29 awards, PSC 8320) and in-vitro diagnostic substances (38 awards, PSC 6635) reflect the consumable-heavy business model and recurring support contracts for installed sequencing platforms.

Oxford Nanopore competes full-and-open across all award activity with no participation in set-aside vehicles. The company's federal footprint skews toward research and development instrumentation for life sciences rather than commercial diagnostics or clinical deployment, positioning it as a specialized research-grade sequencer supplier rather than a systems integrator or clinical-diagnostic vendor.